Bio Cardia, Inc. BCDA
We take great care to ensure that the data presented and summarized in this overview for BioCardia, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BCDA
Top Purchases
Top Sells
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Insider Transactions at BCDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 23
2025
|
Richard M Krasno Director |
BUY
Open market or private purchase
|
Direct |
13,123
+44.65%
|
$13,123
$1.9 P/Share
|
|
Apr 23
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
26,246
+15.89%
|
$26,246
$1.9 P/Share
|
|
Apr 23
2025
|
Simon H Stertzer Director |
BUY
Open market or private purchase
|
Indirect |
104,986
+46.59%
|
$104,986
$1.9 P/Share
|
|
Apr 23
2025
|
Andrew Scott Blank Director |
BUY
Open market or private purchase
|
Indirect |
131,233
+33.04%
|
$131,233
$1.9 P/Share
|
|
Apr 23
2025
|
Bill Facteau Director |
BUY
Open market or private purchase
|
Direct |
13,123
+50.0%
|
$13,123
$1.9 P/Share
|
|
Apr 23
2025
|
David Mc Clung Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
13,123
+23.33%
|
$13,123
$1.9 P/Share
|
|
Apr 15
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
100
+0.09%
|
$200
$2.14 P/Share
|
|
Apr 11
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
300
+0.27%
|
$600
$2.03 P/Share
|
|
Apr 10
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
300
+0.27%
|
$300
$1.99 P/Share
|
|
Apr 07
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.44%
|
$500
$1.96 P/Share
|
|
Apr 04
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
800
+0.71%
|
$1,600
$2.04 P/Share
|
|
Apr 03
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
1,800
+0.81%
|
$3,600
$2.22 P/Share
|
|
Apr 02
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.45%
|
$1,000
$2.23 P/Share
|
|
Mar 05
2025
|
Simon H Stertzer Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.72%
|
$2,000
$2.45 P/Share
|
|
Mar 04
2025
|
Simon H Stertzer Director |
BUY
Open market or private purchase
|
Direct |
15,536
+21.68%
|
$31,072
$2.3 P/Share
|
|
Mar 03
2025
|
Simon H Stertzer Director |
BUY
Open market or private purchase
|
Direct |
22,753
+35.91%
|
$45,506
$2.3 P/Share
|
|
Mar 03
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.46%
|
$1,000
$2.11 P/Share
|
|
Feb 07
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
600
+0.55%
|
$1,200
$2.48 P/Share
|
|
Jan 30
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
239
+0.22%
|
$478
$2.38 P/Share
|
|
Jan 29
2025
|
Peter Altman President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.46%
|
$1,000
$2.4 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 352K shares |
|---|---|
| Grant, award, or other acquisition | 279K shares |
| Payment of exercise price or tax liability | 40.1K shares |
|---|---|
| Grant, award, or other acquisition | 15.8K shares |
| Open market or private sale | 3.26K shares |